Live from AUA2021: Highlights in Overactive Bladder (2021)

Live from AUA2021: Highlights in Overactive Bladder is a panel discussion filmed LIVE at the 2021 AUA Annual Meeting!

This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with OAB.  Panelists will review currently available agents as well as third line therapies, including the pros and cons of each option, and the current data regarding outcomes to facilitate proper patient counseling. Patient communication, including goal setting with respect to realistic expectations of therapy and therapeutic algorithms are important factors in improving patient outcomes.


Acknowledgements

This educational activity is supported by an independent educational grant from:

  • Urovant

Target Audience

  • Urologists

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies.
  2. Realize the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
  3. Discuss optimal use of third line therapies in order to maximize clinical benefit.
  4. Adeptly counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
09/13/2021
Course expires: 
09/13/2022
Rating: 
0

Education Council Disclosures

PDF iconEducation Council Disclosures_ June 2021.pdf

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures 2021.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

 

Course Director(s)

David Ginsberg, MD

has a financial relationship (Scientific Study or Trial (General Urology)) with Bioness;.
has a financial relationship (Consultant or Advisor (General Urology)) with Urovant;.
Faculty(s)

Kathleen Kobashi, MD,MBA

has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Medtronic;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Allergan;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Contura;.

Victor Nitti, MD

has a financial relationship (Investment Interest (Specialty Not Specified)) with Serenity Pharmeuticals;.

Eric Rovner, MD

has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bluewind;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with NextMed;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Allergan;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Hologix;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Valencia;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with NIH/NIDDK;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with astellas;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Urovant;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Medtronics;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and/or listening to the podcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.0 hours

Release Date:  September, 2021
Expiration Date: September, 2024

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.

Registration for this course is complimentary. 


AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance: 

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance, please contact Education@AUAnet.org.